Phase 4 N=72 Alternate Dosing Schedules Study for HPV Vaccine
Cervical Cancer · Genital Warts
Primary: Pain Following HPV Vaccine — 17; 32 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy
Hearing Loss
Primary: CNC Monosyllabic Word Score - Treated Ear — 57.1 percent correct
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=105 Coarctation Of the Aorta Stent Trial
Coarctation of the Aorta
Primary: Change in Difference Between Arm and Leg Systolic Blood Pressure From Baseline to 12 Months — 30 mmHg
Phase 4 N=183 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Depression · Generalized Anxiety Disorder · Panic Disorder
Primary: Change in Mental Health-related Quality of Life From Baseline to 24 Weeks — 8.87; 8.39 units on a scale — p=0.002
N/A N=15 Pilot Study: Safety of a Customized MRI System for Neonatal Imaging
Safety of a Customized NICU MRI System
Primary: Number of Participants With Adverse Events as Measured by Vital Signs, Change in Temperature, and Physical Exam — 0 Adverse Events
Phase 2 N=13 Minocycline in Patients With Alzheimer's Disease
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) — 49; 81; 106; 32.5 units on a scale
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
N/A N=45 Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System
Hearing Loss
Primary: CNC Monosyllabic Word Performance - Treated Ear — 56.8 percent correct
Phase 3 N=676 PEARL Schizophrenia Maintenance
Schizophrenia
Primary: Time to First Relapse Event During Double-blind Phase — NA; 192 days — p=0.039
Phase 2 N=300 Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Japanese Encephalitis · Hepatitis A
Primary: Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection — 15; 13; NA; NA…
Phase 4 N=120 High Dose Vitamin B1 to Reduce Abusive Alcohol Use
Alcoholism
Primary: Change in Average Daily Alcohol Consumption — -3.4; -3.0 alcoholic drinks per day
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
Phase 3 N=591 Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery
Cataract
Primary: The Primary Efficacy Variable is Response Based on the Realisation of the Capsulorhexis Without Use of Any Additive Mydriatic Treatment. — 98.9; 94.7 percentage of…
Phase 3 N=1,537 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134